Increased Risk of MI, Ischemic Stroke After COPD Exacerbation

Share this content:
Increased Risk of MI, Ischemic Stroke After COPD Exacerbation
Increased Risk of MI, Ischemic Stroke After COPD Exacerbation

TUESDAY, June 19, 2018 (HealthDay News) -- For adults with chronic obstructive pulmonary disease (COPD), acute exacerbations are associated with increased risk of myocardial infarction and ischemic stroke, according to a study published online May 3 in the Annals of the American Thoracic Society.

Kieran J. Rothnie, Ph.D., from Imperial College London, and colleagues recruited 5,696 adults with COPD with a first myocardial infarction or ischemic stroke and at least one acute exacerbation to examine the subsequent rates of myocardial infarction and ischemic stroke.

The researchers found that in the 91 days following acute exacerbation, the risks of both myocardial infarction and ischemic stroke were increased. Greater risks were seen following a severe exacerbation (incidence rate ratios, 2.58 and 1.97 for myocardial infarction and ischemic stroke, respectivley) than after a moderate exacerbation (incidence rate ratios, 1.58 and 1.45, respectively). Those with more frequent exacerbations had lower relative risks of myocardial infarction (incidence rate ratio, 1.42 versus 1.69) and ischemic stroke (incidence rate ratio, 1.30 versus 1.68).

"Acute exacerbations of COPD are associated with an increased risk of myocardial infarction and ischemic stroke within 28 days of their onset," the authors write. "Several patient characteristics were identified which are associated with these events."

One author disclosed financial ties to GlaxoSmithKline, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »